HLA-Associated Immune Escape Pathways in HIV-1 Subtype B Gag, Pol and Nef Proteins

Background Despite the extensive genetic diversity of HIV-1, viral evolution in response to immune selective pressures follows broadly predictable mutational patterns. Sites and pathways of Human Leukocyte-Antigen (HLA)-associated polymorphisms in HIV-1 have been identified through the analysis of population-level data, but the full extent of immune escape pathways remains incompletely characterized. Here, in the largest analysis of HIV-1 subtype B sequences undertaken to date, we identify HLA-associated polymorphisms in the three HIV-1 proteins most commonly considered in cellular-based vaccine strategies. Results are organized into protein-wide escape maps illustrating the sites and pathways of HLA-driven viral evolution. Methodology/Principal Findings HLA-associated polymorphisms were identified in HIV-1 Gag, Pol and Nef in a multicenter cohort of >1500 chronically subtype-B infected, treatment-naïve individuals from established cohorts in Canada, the USA and Western Australia. At q≤0.05, 282 codons commonly mutating under HLA-associated immune pressures were identified in these three proteins. The greatest density of associations was observed in Nef (where close to 40% of codons exhibited a significant HLA association), followed by Gag then Pol (where ∼15–20% of codons exhibited HLA associations), confirming the extensive impact of immune selection on HIV evolution and diversity. Analysis of HIV codon covariation patterns identified over 2000 codon-codon interactions at q≤0.05, illustrating the dense and complex networks of linked escape and secondary/compensatory mutations. Conclusions/Significance The immune escape maps and associated data are intended to serve as a user-friendly guide to the locations of common escape mutations and covarying codons in HIV-1 subtype B, and as a resource facilitating the systematic identification and classification of immune escape mutations. These resources should facilitate research in HIV epitope discovery and host-pathogen co-evolution, and are relevant to the continued search for an effective CTL-based AIDS vaccine.

[1]  David Heckerman,et al.  Adaptation of HIV-1 to human leukocyte antigen class I , 2009, Nature.

[2]  Morten Nielsen,et al.  Pan-specific MHC class I predictors: a benchmark of HLA class I pan-specific prediction methods , 2009, Bioinform..

[3]  D. Richman,et al.  2022 update of the drug resistance mutations in HIV-1. , 2022, Topics in antiviral medicine.

[4]  Todd M. Allen,et al.  Protective HLA Class I Alleles That Restrict Acute-Phase CD8+ T-Cell Responses Are Associated with Viral Escape Mutations Located in Highly Conserved Regions of Human Immunodeficiency Virus Type 1 , 2008, Journal of Virology.

[5]  M. Carrington,et al.  HLA-Associated Clinical Progression Correlates with Epitope Reversion Rates in Early Human Immunodeficiency Virus Infection , 2008, Journal of Virology.

[6]  David Heckerman,et al.  Phylogenetic Dependency Networks: Inferring Patterns of CTL Escape and Codon Covariation in HIV-1 Gag , 2008, PLoS Comput. Biol..

[7]  Anthony S Fauci,et al.  An HIV vaccine--challenges and prospects. , 2008, The New England journal of medicine.

[8]  Philip J. R. Goulder,et al.  Impact of MHC class I diversity on immune control of immunodeficiency virus replication , 2008, Nature Reviews Immunology.

[9]  S. Hammer,et al.  HIV Vaccine Research: The Way Forward , 2008, Science.

[10]  S. Hammer,et al.  Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  David Heckerman,et al.  Human leukocyte antigen-specific polymorphisms in HIV-1 Gag and their association with viral load in chronic untreated infection , 2008, AIDS.

[12]  David Heckerman,et al.  Marked Epitope- and Allele-Specific Differences in Rates of Mutation in Human Immunodeficiency Type 1 (HIV-1) Gag, Pol, and Nef Cytotoxic T-Lymphocyte Epitopes in Acute/Early HIV-1 Infection , 2008, Journal of Virology.

[13]  D. Heckerman,et al.  Central Role of Reverting Mutations in HLA Associations with Human Immunodeficiency Virus Set Point , 2008, Journal of Virology.

[14]  John P. Moore,et al.  Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans , 2008, Nature Medicine.

[15]  Dennis R. Burton,et al.  Toward an AIDS Vaccine , 2008, Science.

[16]  Tanmoy Bhattacharya,et al.  HLA Class I-Driven Evolution of Human Immunodeficiency Virus Type 1 Subtype C Proteome: Immune Escape and Viral Load , 2008, Journal of Virology.

[17]  Todd M. Allen,et al.  Structural and Functional Constraints Limit Options for Cytotoxic T-Lymphocyte Escape in the Immunodominant HLA-B27-Restricted Epitope in Human Immunodeficiency Virus Type 1 Capsid , 2008, Journal of Virology.

[18]  D. Heckerman,et al.  Genome-wide HLA-associated-selection in HIV-1 and protein-specific correlations with viral load: An ACTG5142 study , 2008 .

[19]  Morten Nielsen,et al.  Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction , 2007, BMC Bioinformatics.

[20]  N. Letvin.  Correlates of immune protection and the development of a human immunodeficiency virus vaccine. , 2007, Immunity.

[21]  Todd M. Allen,et al.  Escape from the Dominant HLA-B27-Restricted Cytotoxic T-Lymphocyte Response in Gag Is Associated with a Dramatic Reduction in Human Immunodeficiency Virus Type 1 Replication , 2007, Journal of Virology.

[22]  Todd M. Allen,et al.  Escape and Compensation from Early HLA-B57-Mediated Cytotoxic T-Lymphocyte Pressure on Human Immunodeficiency Virus Type 1 Gag Alter Capsid Interactions with Cyclophilin A , 2007, Journal of Virology.

[23]  David Heckerman,et al.  Evidence of Differential HLA Class I-Mediated Viral Evolution in Functional and Accessory/Regulatory Genes of HIV-1 , 2007, PLoS pathogens.

[24]  D. Heckerman,et al.  Founder Effects in the Assessment of HIV Polymorphisms and HLA Allele Associations , 2007, Science.

[25]  D. Nixon,et al.  Sequential Broadening of CTL Responses in Early HIV-1 Infection Is Associated with Viral Escape , 2007, PloS one.

[26]  Mathias M Schuler,et al.  SYFPEITHI: database for searching and T-cell epitope prediction. , 2007, Methods in molecular biology.

[27]  David Heckerman,et al.  CD8+ T-cell responses to different HIV proteins have discordant associations with viral load , 2007, Nature Medicine.

[28]  Todd M. Allen,et al.  HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to the Initial CD8+ T Cell Response against HIV-1 , 2006, PLoS medicine.

[29]  David Heckerman,et al.  Leveraging Information Across HLA Alleles/Supertypes Improves Epitope Prediction , 2006, RECOMB.

[30]  B. Walker,et al.  Fitness Cost of Escape Mutations in p24 Gag in Association with Control of Human Immunodeficiency Virus Type 1 , 2006, Journal of Virology.

[31]  Bette T. Korber,et al.  Relative Dominance of Gag p24-Specific Cytotoxic T Lymphocytes Is Associated with Human Immunodeficiency Virus Control , 2006, Journal of Virology.

[32]  Tao Dong,et al.  Conflicting selective forces affect T cell receptor contacts in an immunodominant human immunodeficiency virus epitope , 2006, Nature Immunology.

[33]  J. Goedert,et al.  AIDS restriction HLA allotypes target distinct intervals of HIV-1 pathogenesis , 2005, Nature Medicine.

[34]  Christian Brander,et al.  Selective Escape from CD8+ T-Cell Responses Represents a Major Driving Force of Human Immunodeficiency Virus Type 1 (HIV-1) Sequence Diversity and Reveals Constraints on HIV-1 Evolution , 2005, Journal of Virology.

[35]  O. Lund,et al.  An integrative approach to CTL epitope prediction: A combined algorithm integrating MHC class I binding, TAP transport efficiency, and proteasomal cleavage predictions , 2005, European journal of immunology.

[36]  D. Cooper,et al.  A new variant cytotoxic T lymphocyte escape mutation in HLA-B27-positive individuals infected with HIV type 1. , 2005, AIDS research and human retroviruses.

[37]  Richard A Koup,et al.  T cell receptor recognition motifs govern immune escape patterns in acute SIV infection. , 2004, Immunity.

[38]  Philip J. R. Goulder,et al.  HIV and SIV CTL escape: implications for vaccine design , 2004, Nature Reviews Immunology.

[39]  Alessandro Sette,et al.  Selection, Transmission, and Reversion of an Antigen-Processing Cytotoxic T-Lymphocyte Escape Mutation in Human Immunodeficiency Virus Type 1 Infection , 2004, Journal of Virology.

[40]  M. Altfeld,et al.  Immune Selection for Altered Antigen Processing Leads to Cytotoxic T Lymphocyte Escape in Chronic HIV-1 Infection , 2004, The Journal of experimental medicine.

[41]  F. M. Marincola,et al.  Consistent Cytotoxic-T-Lymphocyte Targeting of Immunodominant Regions in Human Immunodeficiency Virus across Multiple Ethnicities , 2004, Journal of Virology.

[42]  Todd M. Allen,et al.  HIV evolution: CTL escape mutation and reversion after transmission , 2004, Nature Medicine.

[43]  Marion Cornelissen,et al.  Identification of Sequential Viral Escape Mutants Associated with Altered T-Cell Responses in a Human Immunodeficiency Virus Type 1-Infected Individual , 2003, Journal of Virology.

[44]  Stephen J O'Brien,et al.  The influence of HLA genotype on AIDS. , 2003, Annual review of medicine.

[45]  David W. Haas,et al.  A Multi-Investigator/Institutional DNA Bank for AIDS-Related Human Genetic Studies: AACTG Protocol A5128 , 2003, HIV clinical trials.

[46]  John D. Storey,et al.  Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[47]  C. Moore,et al.  Evidence of HIV-1 Adaptation to HLA-Restricted Immune Responses at a Population Level , 2002, Science.

[48]  M. Mulligan,et al.  Magnitude of Functional CD8+ T-Cell Responses to the Gag Protein of Human Immunodeficiency Virus Type 1 Correlates Inversely with Viral Load in Plasma , 2002, Journal of Virology.

[49]  Edward C. Holmes,et al.  Clustered Mutations in HIV-1 Gag Are Consistently Required for Escape from Hla-B27–Restricted Cytotoxic T Lymphocyte Responses , 2001, The Journal of experimental medicine.

[50]  J. Klein,et al.  The HLA system. First of two parts. , 2000, The New England journal of medicine.

[51]  S. Hammer,et al.  Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. , 2000, JAMA.

[52]  D. Montefiori,et al.  Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. , 1999, Science.

[53]  H. Clifford Lane,et al.  Administration of an Anti-CD8 Monoclonal Antibody Interferes with the Clearance of Chimeric Simian/Human Immunodeficiency Virus during Primary Infections of Rhesus Macaques , 1998, Journal of Virology.

[54]  Wiklund Ra,et al.  First of two parts , 1997 .

[55]  P. Klenerman,et al.  Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[56]  Xiping Wei,et al.  Antiviral pressure exerted by HIV-l-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus , 1997, Nature Medicine.

[57]  J. Goedert,et al.  Influence of combinations of human major histocompatibility complex genes on the course of HIV–1 infection , 1996, Nature Medicine.

[58]  G. Shaw,et al.  Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection , 1994, Journal of virology.

[59]  R. Koup.  Virus escape from CTL recognition , 1994, The Journal of experimental medicine.

[60]  D. Ho,et al.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome , 1994, Journal of virology.

[61]  Charles R. M. Bangham,et al.  Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition , 1991, Nature.

[62]  C Dosne Pasqualini,et al.  The HLA system. , 1979, Medicina.